Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.095
Sell
RSI(14)
33.485
Neutral
STOCH(KDJ)(9,3,3)
15.131
Sell
ATR(14)
0.379
Low Volatility
CCI(14)
-154.066
Sell
Williams %R
98.496
Oversold
TRIX(12,20)
-0.627
Sell
StochRSI(14)
0.000
Sell
Foghorn Therapeutics Inc.
FHTX4.370USD
-0.530-10.82%
Market hours （ET）Quotes delayed by 15 min
47.54MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Foghorn Therapeutics Inc.
Currency: USD Updated: 2026-03-27Key Insights
Foghorn Therapeutics Inc.'s fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 105 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 11.62.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Foghorn Therapeutics Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Foghorn Therapeutics Inc. Highlights
StrengthsRisks
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.91M.
Fairly Valued
The company’s latest PE is -3.82, at a medium 3-year percentile range.
Held by Invesco
Star Investor Invesco holds 2.71K shares of this stock.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
11.625
Target Price
+137.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Foghorn Therapeutics Inc. is 5.96, ranking 304 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 9.25M, representing a year-over-year increase of 223.77%, while its net profit experienced a year-over-year increase of 11.08%.
Score
Financials
5.37
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.79
Operational Efficiency
2.72
Growth Potential
6.80
Shareholder Returns
7.11
Foghorn Therapeutics Inc.'s Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Foghorn Therapeutics Inc. is 6.52, ranking 256 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.82, which is -68.74% below the recent high of -1.19 and -55.09% above the recent low of -5.92.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 105/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Foghorn Therapeutics Inc. is 9.00, ranking 19 out of 391 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 14.00 and a low of 9.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
11.625
Target Price
+137.24%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Foghorn Therapeutics Inc.
FHTX
10
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Foghorn Therapeutics Inc. is 6.24, ranking 257 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.39 and the support level at 4.04, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.844
Sell
MA10
4.902
Sell
MA20
5.191
Sell
MA50
5.511
Sell
MA100
5.168
Sell
MA200
5.082
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Foghorn Therapeutics Inc. is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 74.66%, representing a quarter-over-quarter decrease of 0.30%. The largest institutional shareholder is The Vanguard, holding a total of 1.93M shares, representing 3.29% of shares outstanding, with 0.15% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Flagship Ventures
Fidelity Management & Research Company LLC
BVF Partners L.P.
Eli Lilly and Company
Kadoch (Cigall)
Deerfield Management Company, L.P.
Raymond James & Associates, Inc.
The Klarman Family Foundation
BlackRock Institutional Trust Company, N.A.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Foghorn Therapeutics Inc. is 2.70, ranking 205 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 3.12. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
3.09
VaR
+8.16%
240-Day Maximum Drawdown
+45.69%
240-Day Volatility
+82.66%
Return
Best Daily Return
60 days
+23.64%
120 days
+23.64%
5 years
+55.45%
Worst Daily Return
60 days
-12.92%
120 days
-16.15%
5 years
-25.12%
Sharpe Ratio
60 days
-0.37
120 days
+0.36
5 years
+0.22
Risk Assessment
Maximum Drawdown
240 days
+45.69%
3 years
+71.43%
5 years
+87.67%
Return-to-Drawdown Ratio
240 days
+0.67
3 years
-0.14
5 years
-0.14
Skewness
240 days
+0.56
3 years
+1.59
5 years
+1.80
Volatility
Realised Volatility
240 days
+82.66%
5 years
+101.47%
Standardised True Range
240 days
+8.23%
5 years
+14.97%
Downside Risk-Adjusted Return
120 days
+57.50%
240 days
+57.50%
Maximum Daily Upside Volatility
60 days
+64.88%
Maximum Daily Downside Volatility
60 days
+58.23%
Liquidity
Average Turnover Rate
60 days
+0.21%
120 days
+0.22%
5 years
--
Turnover Deviation
20 days
-37.25%
60 days
-18.94%
120 days
-17.17%
Peer Comparison
Biotechnology & Medical Research
Foghorn Therapeutics Inc.
FHTX
6.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
